RecruitingPhase 1Drug trialBioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian CancerA Multicenter, Open-label, Randomized, Multi-dose, 2-sequence, 2-period, Crossover Bioequivalence Study to Comparison of the Pharmacokinetics and Safety of DWZ2501 and DWC202510 in Patients with Advanced BRCA-mutated High-grade Ovarian Cancer